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Abstract
Background:  Neutropenic enterocolitis is a life-threatening complication most frequently
occurring after intensive chemotherapy in acute leukaemias. Gramnegative bacteria constitute the
most important group of causative pathogens. Fungi have also been reported, but their practical
relevance remains unclear. The guidelines do not address concrete treatment recommendations
for fungal neutropenic enterocolitis.
Methods: Here, we conducted a metaanalysis to answer the questions: What are frequency and
mortality of fungal neutropenic enterocolitis? Do frequencies and microbiological distribution of
causative fungi support empirical antimycotic therapy? Do reported results of antimycotic therapy
in documented fungal neutropenic enterocolitis help with the selection of appropriate drugs?
Following a systematic search, we extracted and summarised all detail data from the complete
literature.
Results: Among 186 articles describing patients with neutropenic enterocolitis, we found 29
reports describing 53 patients with causative fungal pathogens. We found no randomised
controlled trial, no good quality cohort study and no good quality case control study on the role
of antifungal treatment. The pooled frequency of fungal neutropenic enterocolitis was 6.2%
calculated from all 860 reported patients and 3.4% calculated from selected representative studies
only. In 94% of the patients, Candida spp. were involved. The pooled mortality rate was 81.8%. Most
authors did not report or perform antifungal therapy.
Conclusion: In patients with neutropenic enterocolitis, fungal pathogens play a relevant, but
secondary role compared to bacteria. Evidence concerning therapy is very poor, but
epidemiological data from this study may provide helpful clues to select empiric antifungal therapy
in neutropenic enterocolitis.
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Background
Neutropenic enterocolitis is the most important and a
highly life-threatening abdominal infection in neutro-
penic patients. This complication most frequently occurs
after intensive chemotherapy in acute leukaemias. The
pooled incidence, derived from all available studies, was
calculated to be 5.3% in patients hospitalised for haema-
tological malignancies, for high- dose chemotherapy in
solid tumors or for aplastic anaemia [1]. The literature
provides generally poor evidence on the treatment of neu-
tropenic enterocolitis.
In a previous systematic review, we could not find pro-
spective trials nor case control studies on any part of ther-
apy [1]. The most intensively discussed therapeutic
question in the past decades is whether patients with neu-
tropenic enterocolitis should receive conservative or surgi-
cal therapy. In contrast, the differential options of medical
management consume much lesser space in the discus-
sion sections. Gramnegative bacteria constitute the most
important group of causative pathogens [2-5]. There is a
consensus that immediate empirical broad spectrum anti-
biotic therapy is mandatory, but it is unclear which anti-
biotic is the drug of choice for empirical therapy. After all,
application of a modified recommendation of the current
IDSA guidelines for the treatment of neutropenic patients
with unexplained fever can be regarded as reasonable to
select appropriate antibiotics [1,6].
The role of fungi as causative organisms is even more
obscure. In conventional reviews on neutropenic entero-
colitis, sometimes citations concerning detection of Cand-
ida spp. in blood cultures can be found [7-9]. In case series
and cohort studies, frequencies of causative fungi are
either not given or differ largely from 0% up to more than
19% in autopsy studies [10]. In a paediatric study, 16% of
the organisms, cultured premortem from blood, were
fungi. Moreover, in this report fungal pathogens
accounted for 53% of new microorganisms seen at
autopsy [11]. Mortality has been reported to be up to
100% in patients with fungaemia [2]. The latter studies
suggest a high relevance of fungal pathogens. Changes in
the intestinal flora, due to frequent use of broad spectrum
antibiotics in neutropenic patients, might support fungal
invaders. Surprisingly, the need for an empirical antimy-
cotic therapy is nearly never discussed in reports describ-
ing patients with fungal neutropenic enterocolitis.
Similarly, guidelines give no clear recommendations for
the management of these patients. IDSA guidelines for the
use of antimicrobial agents in neutropenic patients with
cancer [6], generally, make very few recommendations
concerning abdominal infections. Particularly, no state-
ment regarding the indication for antimycotic therapy in
neutropenic enterocolitis is given. The use of empirical
antimycotic therapy is not recommended as a necessary
component of the first-line antimicrobial therapy of neu-
tropenic patient with unexplained fever. Hughes et al.
state that, although clinicians disagree as to when, and
even if, amphotericin B therapy should be introduced
empirically, most believe that the patient who remains
febrile and profoundly neutropenic for >5 days, despite
the administration of broad-spectrum antibiotics in ade-
quate dosages, is a candidate for antifungal therapy.
On the other hand, there are clinically documented infec-
tions in neutropenia in which first line empirical antimy-
cotic therapy can be regarded as standard. The guidelines
of the German Society of Haematology and Oncology rec-
ommend that in febrile neutropenic patients with severe
neutropenia (i.e. lasting for more than 10 days) and lung
infiltrates, initial antimicrobial therapy should include
amphotericin B [12]. The markedly poorer prognosis of
both neutropenic enterocolitis [1] and pneumonia [13]
compared to fever of unknown origin (FUO) might sug-
gest that early antifungal could be also beneficial for
patients suffering from neutropenic enterocolitis.
For these reasons, we conducted this analysis. Following a
systematic search, we extracted and summarised all detail
data (if possible, single patient data) from the complete
literature to enhance evidence regarding the question
whether a routine empirical antimycotic therapy should
be administered as a parallel with broad-spectrum antibi-
otic therapy.
Methods
The following clinical questions were posed in this sys-
tematic review: What is the frequency of invasive fungal
infections in neutropenic enterocolitis? What is the mor-
tality of fungal neutropenic enterocolitis? Does the fre-
quency and the microbiological distribution of invasive
fungal infections support empirical antimycotic therapy?
Do reported results of antimycotic therapy in documented
fungal neutropenic enterocolitis help with the selection of
appropriate drugs?
Identification and selection of relevant reports
We performed a computerised search of the MEDLINE
database (PubMed version) for appropriate articles, pub-
lished from 1953 (including Oldmedline) through April
2005, in any language. The keywords used were "neutro-
penic enterocolitis" (MeSH search term), "neutropenic
colitis" and "typhlitis and (neutrop* or granulocyt*)".
Subsequently, reference lists of all identified reports, stud-
ies and reviews in the field were screened. We excluded
articles describing paediatric patients, describing Clostrid-
ium difficile colitis only, not dealing with neutropenic
enterocolitis or duplicate publications. We reviewed the
titles and abstracts of all potentially pertinent articles for
inclusion. In articles with unclear relevance and in allBMC Infectious Diseases 2006, 6:35 http://www.biomedcentral.com/1471-2334/6/35
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included articles full text versions were checked. Concern-
ing definition of neutropenic enterocolitis and grading of
evidence we refer to our previous study [1]. Studies,
describing typhlitis or necrotising enterocolitis during
neutropenia, which we considered as sub-entities of neu-
tropenic enterocolitis were included.
Data extraction
The data were extracted independently by at least two
researchers. Discrepancies were solved by consensus dis-
cussion including a third researcher. From articles that
met inclusion criteria, individual patient data concerning
fungal pathogens were extracted. The frequencies of fun-
gal pathogens were analysed and the findings were sum-
marised. In some studies, several patients with fungal
neutropenic enterocolitis are described, but the exact
number is not determinable. In such circumstances, the
minimum number of patients was included in our analy-
sis. These studies were not included in the calculation of
the pooled frequency of fungal neutropenic enterocolitis
from representative studies (see below).
Definition of proven fungal infection
Only proven invasive fungal bowel infections were ana-
lysed. The definitions adhered to the criteria of Ascioglu et
al. [14]. A fungal infection was considered invasive when
blood or ascites cultures yielded yeasts with temporally
related clinical signs or when fungi could be detected
microscopically inside the bowel wall with evidence of
associated tissue damage (including ulceration). Detec-
tion of fungi in cultures of stool or bowel specimens at
autopsy was not considered as proof of invasive fungal
infection. Probable or possible fungal infections were not
analysed, due to the very heterogeneous reporting of
detail data, especially concerning indirect criteria for sus-
picious patients.
Further definitions
Laparotomy with no resection was not considered as sur-
gical therapy. The pooled frequency of fungal neutropenic
enterocolitis among patients with neutropenic enterocol-
itis was calculated with two methods: (1) The "pooled fre-
quency of fungal neutropenic enterocolitis from all
reported patients" was calculated by division of the sum
of all patients with fungal neutropenic enterocolitis from
all relevant studies by the sum of all reported patients with
neutropenic enterocolitis. (2) The "pooled frequency of
fungal neutropenic enterocolitis from representative stud-
ies" was calculated by division of the sum of all patients
with fungal neutropenic enterocolitis from representative
studies by all patients with neutropenic enterocolitis in
these studies. Exclusion criteria for these representative
studies in this sense were: (a) Studies from the perspective
of pathologists (autopsy studies), (b) studies from the
perspective of surgeons, (c) studies in which reporting of
microbiological data (analysis of pathogens) was insuffi-
cient (most radiological studies) and (d) studies describ-
ing less than 4 patients with neutropenic enterocolitis.
Statistics
95%-confidence intervals for proportions (Wilson
method) were calculated with the statistical package CIA
confidence interval analysis from the book "Statistics with
Confidence" 2nd ed. (Eds: Altman, Machin, Bryant and
Gardner) [15]. Differences between categorical variables
were tested with univariate χ2-tests.
Results
A MEDLINE search, as of 15 March 2005, with the search
terms "neutropenic enterocolitis or neutropenic colitis"
and "typhlitis and (neutrop* or granulocyt*)" yielded
286 articles. This represented an extension to a previously
reported search strategy [1]. After individual review of
these titles and abstracts, we excluded 87 articles describ-
ing paediatric patients, five articles describing Clostridium
difficile colitis and 55 other articles, not dealing with neu-
tropenic enterocolitis, reviews without primary data or
duplicate publications. After this selection, 139 articles
were remaining. Additional hand search in reference lists
of these reports and reviews revealed further 47 relevant
articles, whose reference lists were also screened. Finally a
total of 186 articles were found to be relevant and their
full text versions were studied. Among these we found,
again, no study on neutropenic enterocolitis that fulfilled
the criteria for evidence levels 1a to 3b according to Phil-
lips et al. [16]. We found no systematic review, no ran-
domised controlled trial, no good quality cohort study
and no good quality case control study on any part of
therapy, particularly, on the role of antifungal treatment.
Eighty-four reports of evidence level 4 (case series or poor
quality cohort or poor quality case control studies) were
detected. One-hundred and two reports of evidence level
5 (expert opinion) were found.
Studies reporting of fungal neutropenic enterocolitis
In 29 of 186 relevant papers, a total of 53 patients suffer-
ing from neutropenic enterocolitis associated with proven
invasive fungal infection were reported (Table 1). In 22 of
these cases, fungi were detected in blood cultures. In 26
patients, fungi were observed histologically in the bowel
wall and in 4 patients, fungi were detected in both types
of material. No case of detection of fungi in the ascitic
fluid, but one case of isolation of Candida albicans in a
peritoneal lavage was reported. Underlying diseases of
these 53 patients included acute myeloid leukaemia (21
pts.), acute lymphatic leukaemia (3 pts.), acute leukaemia
not specified (7 pts.), lymphoma (2 pts.), multiple mye-
loma (1 pt.), haematological malignancies not specified
(8 pts.), malignancies not specified but probably haema-
tological (8 pts.), non-small cell lung cancer (1 pt.) andBMC Infectious Diseases 2006, 6:35 http://www.biomedcentral.com/1471-2334/6/35
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Table 1: Studies reporting patients with fungal neutropenic enterocolitis
Study Study type No. pts. with 
fungal NE
Disease OP? Outcome Spec. Pathogen Additional study details
[45] CR 1 AML OP survived Histology Candida spp. + 
grampositive cocci
CR providing sufficient details
[46] CS2C 1 ALL OP survived Blood culture+ 
histology
Candida spp. CR providing sufficient 
details, 1 case of IFI among 2 
cases of NE
[47] PCS 1 HMNS n.s. dead Blood culture Candida spp. Early detailled autopsy series 
(69 pts), 1 confirmed 
fungaemia, 3 questionable 
cases of IFI
[48] MCS 4 (or more) AML n.s. n.s. Blood culture Candida spp. Acurate retrospective study 
of D-Xylose malabsorption 
in110 AML patients. 
Malabsorption was associated 
with candidemia but no. of 
patients with this 
combination was not 
completely clear
[22] CR 1 AML NOP survived Blood culture Candida albicans + 
P.aeruginosa.
CR providing sufficient details
[19] MCS 5 AL n.s. dead Histology Candida albicans 3 
pts Candida glabrata 
1 pt Aspergillus 
fumigatus 1 pt
Large retrospective study. 
Important description of 
bowel wall thickening as 
negative prognostic factor in 
88 pat. with NE. Limitation: 
Blood culture results are not 
reported.
[49] CS3C 1 HMNS OP survived Blood culture Fungus n.s. CS of 3 pat. with NE 
(1*fungaemia) among 18 pat. 
with abdominal 
complications. Few patient 
details. Pat. were not 
consecutive.
[50] CS2C 1 AML OP survived Blood culture Candida spp. CR providing sufficient 
details, 1 case of IFI among 2 
cases with NE
[10] PCS 5 (or more) MNS n.s. dead Blood culture / 
histology
Candida tropicalis 2 
pts Candida albicans 
1 pt Candida spp. 2 
pts
Interesting autopsy series 
describing heterogeneity in 
the pathologic features of NE. 
Microbiologic data are not 
clearly linked to individual 
patients. No. of pat with IFI 
was not exactly described.
[51] SCS 1 AA OP Dead Histology Candida spp. + 
bacteria
Acurate CS of 8 pat. with NE 
(1*IFI). Pat. were not 
consecutive.
[52] CS2C 1 AA NOP Dead Histology Candida spp. CR providing sufficient details
[53] CS3C 1 HNHL OP survived Histology Candida spp. Larger CS of 3 pat. with NE 
(1*IFI) among 56 pat. with 
abdominal complications 
necessitating surgery. Pat. 
were not consecutive.
[27] MCS 1 HMNS NOP n.s. Blood culture Candida glabrata + 
Enterococcus spp.
Cohort study comparing 18 
definite and 11 clinically 
diagnosed consecutive cases 
of NE. Substantial review.
[4] MCS 2 AML 
ALL
NOP dead Blood culture 1 /
histology 1
Aspergillus fumigatus 
1 pt Candida krusei
Cohort study describing 13 
consecutive cases of NE.
[54] CS3C 1 AML NOP Dead Histology Cryptococcus 
neoformans
CR providing sufficient details 
of an uncommon course and 
pathogen
[17] MCS 1 ALL n.s. Dead Blood culture Candida spp. 
(+Aspergillus ?)
Cohort study describing 13 
consecutive cases of NE.BMC Infectious Diseases 2006, 6:35 http://www.biomedcentral.com/1471-2334/6/35
Page 5 of 11
(page number not for citation purposes)
[55] CS2C 1 MM OP Dead Blood culture Candida tropicalis + 
Staph.aureus + E.coli
CR providing sufficient 
details, 1 case of IFI among 2 
cases of NE
[21] CR 1 AML NOP Dead Blood culture Candida krusei CR providing sufficient details











Cohort study describing 10 
consecutive cases of NE.
[56] MCS 2 AL OP1 
NOP
1
Dead Histology Candida spp. Case series describing 10 
consecutive cases of NE. 
Patients were consecutive, 
but only patients with 
histologic confirmation were 
analysed.
[29] MCS 1 AML n.s. survived Blood culture Candida albicans Cohort study describing 7 
consecutive cases of NE.
[57] MCS 4 HMNS n.s. Dead Histology Candida spp. Early large autopsy series. 
Relatively few individual 
patient data provided.
[58] CR 1 NSCLC OP Dead Peritoneal lavage Candida albicans CR providing sufficient details
[59] CR 1 AML OP survived Histology Fungus n.s. + 
bacteria n.s.
Short but sufficiently detailled 
case report embedded in a 
review emphasizing nursing 
actions
[2] SCS 3 MNS NOP Dead Blood culture Candida spp. CS including 18 pat. with 
clinically diagosed NE 
(3*fungaemia) among 58 pat. 
with abdominal 
complications. Few patient 
details. Pat. were not 
consecutive.
[60] PCS 2 AML NOP Dead Histology Candida spp. Early smaller (6 patients with 
NE) but detailled autopsy 
case series.
[61] RCS 2 AML OP Dead Histology + Blood 
culture 1pt 
Histology 1pt
Candida spp. 1pt 
Candida spp.+ 
bacteria n.s. 1 pt
Smaller (6 patients with NE) 
but detailled radiological case 
series.
[62] MCS 1 or more HMNS NOP Dead Histology Fungus n.s Cohort study describing 34 
consecutive cases of NE. No. 
of pat with IFI was not exactly 
described.
[28] SCS 1 LY NOP Dead Histology Candida spp. Case series describing 22 
patients with NE. Pat. were 
not consecutive. Relatively 
few individual microbiological 





ns, not specified; NE, neutropenic enterocolitis; IFI, invasive fungal infection; AML, acute myeloid leukaemia; ALL, acute lymphatic leukemia; MM, 
multiple myeloma;
AL, acute leukaemia; CL, chronic leukemias; MNS, malignancy not specified; HMNS, haematological malignancy not specified; LY, lymphoma; 
NCCLC, non-small cell lung cancer; pts patients; OP, operated; NOP, not operated; CR, case report; CS3C, case series with 3 cases; MCS, medical 
case series; PCS, pathological case series; RCS radiological case series; SCS, surgical case series
Table 1: Studies reporting patients with fungal neutropenic enterocolitis (Continued)BMC Infectious Diseases 2006, 6:35 http://www.biomedcentral.com/1471-2334/6/35
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aplastic anaemia (2 pts.). In 20 of 29 articles, histopatho-
logical evidence, which we still consider as the gold stand-
ard, confirmed the diagnosis of neutropenic enterocolitis.
In 3 articles a clinical diagnosis fulfilling our previously
suggested criteria [1] was established. In 6 articles, authors
provided several symptom criteria (e.g. abdominal pain),
but did not specify whether one criterion or specific com-
binations was sufficient for diagnosis and whether radio-
logical confirmation was obligatory or not.
Causative pathogens
In 3 patients, invasive fungal infection with no further
specification of the pathogen was diagnosed. In 94% (47/
50) of the remaining patients, Candida  spp. were
involved. In 32 patients, the pathogens were reported as
Candida spp. without a species description. In one of these
patients, the blood culture contained also Aspergillus spp.
[17]. However, a single detection of Aspergillus  spp. in
blood cultures is commonly not considered as proof of an
invasive fungal infection due to the risk of false-positive
results by environmental contamination [14,18]. In 18
patients, a species description of the fungal pathogen was
provided: Candida albicans (7 pat.), Aspergillus fumigatus (2
pat.), Candida tropicalis (3 pat.), Candida glabrata (2 pat.),
Candida krusei (2 pt.), Cryptococcus neoformans (1 pt.). Can-
dida guillermondi + Trichosporon beigelii in the same blood
culture (1 pt.). In 10 patients, it was not clearly reported
whether also bacteria were involved in the infection. In
30.2% (13/43) of the remaining patients, equally causa-
tive bacteria were observed either in blood cultures or in
the bowel wall (species not specified (8 pts.), gram-posi-
tive cocci (1 pt.), Enterococcus sp. (1 pt.), Pseudomonas aer-
uginosa (1 pt.), Staph. aureus + Escherichia coli (1 pt.), P.
aeruginosa + E. coli + Klebsiella pneumoniae (1 pt.)). In 30
patients, fungi were considered to be exclusively causative.
One of the patients of our institution had a proven inva-
sive small bowel infection with Aspergillus fumigatus [4].
Neutropenic enterocolitis caused by moulds is extremely
rare. Only one further case is published [19]. Our patient
was a 63-year old man with AML already neutropenic on
admission (WBC count: 0.1 G/l without recovery). On
day 9, after chemotherapy with fludarabine, high-dose
cytarabine and dexamethasone (FLAG-Ida) he developed
paralytic subileus, abdominal pain, vomiting, meteorism
and fever. There was no improvement with broad-spec-
trum antibiotics and amphotericin B for 11 days. Death
occurred on day 25 after chemotherapy due to sepsis.
Autopsy revealed an ulcer in the middle of the jejunum,
with a diameter of 3 cm, caused by Aspergillus fumigatus
and the same pathogen as causative agent of concomitant
pneumonia [4].
Therapy and prognosis
In 25 patients, it was unclear whether they were treated
conservatively or surgically. Of the remaining 28 patients,
13 patients (46.4%) were reported to be treated surgically
and 15 (53.6%) were managed conservatively. In 33
patients, it was not described that any antifungal therapy
was given. In 20 patients, with proven fungal neutropenic
enterocolitis at least some information regarding antifun-
gal therapy was provided: The antimycotic therapy of 4
surviving patients is described below. Regarding the fatal
cases, Cartoni et al. reported that empirical antibiotic ther-
apy was given followed by empirical antifungal agents in
selected cases. We assume that this was the case in five
patients, which we included as fungal neutropenic entero-
colitis. In the study of Micozzi et al., selected patients,
probably also those five patients which we considered to
have fungal neutropenic enterocolitis, received amphoter-
icin B [20]. It was not specified whether therapy was
empirical or following microbiological documentation.
Starnes et al. reported that antimycotics were not success-
ful in all 3 patients with candidaemia [2]. In our own
series, in both patients, treatment with amphotericin B (1
mg/kg/d) was not successful [4]. McIlroy et al. observed a
break-through infection with Candida krusei despite
empirical fluconazole in one patient with clinical diagosis
of neutropenic enterocolitis. Unfortunately, even a
change to amphotericin B was not successful [21].
In 9 of the 53 patients, it was unclear whether they sur-
vived or died in the course of infection. From the remain-
ing 44 patients, 36 died and the pooled mortality rate was
calculated to be 81.8% 36/44 pts., 95%-CI: 68–91 %).
Seven of them had been operated on. Thirteen patients
were treated conservatively. In 16 patients the type of
treatment was not specified. Eight patients (18.2%) sur-
vived. Six of them had been operated on. One patient was
treated conservatively, in one patient the type of treatment
was not specified. In 4 of the 8 survivors, antifungal ther-
apy was not described. Three patients received antifungal
therapy, which was not specified. One patient received
fluconazole empirically, which was changed in the course
to amphotericin B [22]. Three patients were described to
recover early from neutropenia, in the other 5, no data
concerning recovery of haematopoesis were provided.
Calculation of pooled frequency rates
The pooled frequency of fungal neutropenic enterocolitis
among patients with neutropenic enterocolitis was calcu-
lated with two methods. Both have advantages and disad-
vantages:
1. The pooled frequency of fungal neutropenic enterocol-
itis from all reported patients was calculated to be 6.2%
(53/860 95%-CI: 4.7–8.0%). This method includes all
available information, but is limited by multiple selectionBMC Infectious Diseases 2006, 6:35 http://www.biomedcentral.com/1471-2334/6/35
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biases (selection of more severe autopsied or operated
cases).
2. The pooled frequency of fungal neutropenic enterocol-
itis from 12 representative studies (Table 2) was calcu-
lated to be 3.4% (5/146; 95%-CI: 1.5–7.8%). This
method includes only a smaller part of available informa-
tion, but selection bias is reduced as much as possible.
However, fungal neutropenic enterocolitis may be under-
estimated, since only few histologic specimens were
included and the sensitivity of the diagnostic methods is
limited.
Prospective diagnostic surveillance studies
Four of 186 papers were prospective diagnostic surveil-
lance studies [23-26]. In none of the 28 patients of these
studies, was a proven invasive fungal enterocolitis
described. In one study, Girmenia et al. assessed the role
of Candida spp. in 20 consecutive patients with neutro-
penic enterocolitis by an assay for Candida mannoprotein
antigen [24].
Discussion
This is the first analysis on the relevance of fungal patho-
gens in neutropenic enterocolitis of adults, based on a sys-
tematic analysis of the literature (including our own
primary data). The approach was to extract the complete
detail data from the studies and to increase evidence by
pooling analyses. The maximum number of clearly
described patients in a single study was 5, which is to low
to perform conclusive statistics concerning frequency,
mortality, spectrum of causative species or therapy. A dis-
cussion about this question is lacking in the literature,
especially in contrast to the extensive debate concerning
the role of surgery.
Our study revealed several important results: (1) We
found that a total number of 53 patients with fungal neu-
tropenic enterocolitis in adults was described in 29
papers. (2) The pooled frequency of fungal neutropenic
enterocolitis was 6.2% calculated from all reported 860
patients and 3.4% calculated from representative studies
only. (3) In 94% of the patients Candida  spp. were
Table 2: Representative studies included for calculation of pooled frequency of fungal neutropenic enterocolitis
Study Study type Underlying diseases No. FNE No. NE Additional study details
[5] Retrospective MCS AL and CL 0 20 Detailled cohort study describing 20 consecutive 
patients with NE
[27] Retospective MCS Mostly AL (some solid 
tumors).
1 29 Cohort study comparing 18 definite and 11 clinically 
diagnosed consecutive cases of NE. Substantial review.
[4] Retrospective MCS AL. Some other abdominal 
infections in other 
neutropenic pts. are 
described
2 13 Cohort study describing 13 consecutive cases of NE.
[23] Prospective diagnostic 
study
AL 0 4 Relatively small but prospective ultrasound -based 
diagnostic study applying exactly defined diagnostic 
criteria
[63] Retrospective MCS AML 0 10 Cohort study describing 10 consecutive cases of NE. 
Relatively brief, but sufficient data
[64] Retrospective MCS AL 0 9 Detailled cohort study describing 9 consecutive 
patients with NE
[65] Retrospective MCS Metastatic breast cancer 
receiving docetaxel-based 
chemotherapy.
0 4 Small cohort study in taxane-exposed patients. 
Relatively brief, but sufficient data.
[17] Retrospective MCS AL 1 13 Cohort study describing 13 consecutive cases of NE.
[66] Retrospective MCS Cancer pts receiving 
taxane-based 
chemotherapy
0 5 Cohort study describing few consecutive patients with 
NE among 4600 courses of taxane-based therapy. 
Relatively brief, but sufficient data.
[18] Retrospective MCS AML 0 12 Detailled cohort study describing 12 consecutive 
patients with NE within an analysis of all infections in 
pat. receiving cheomtherapy
[29] Retrospective MCS AML 1 7 Cohort study describing 7 consecutive cases of NE.
[3] Retrospective SCS 
reporting of consecutive 
patients
AL and some pts with CL. 0 20 The only surgical cohort study describing consecutive 
patients. Relatively brief, but sufficient data.
Total 5 146
FNE, fungal neutropenic enterocolitis; ns, not specified; NE, neutropenic enterocolitis; AML, acute myeloid leukaemia; AL, acute leukaemia; CL 
chronic leukemias; pts, patient; MCS, medical case series; SCS, surgical case seriesBMC Infectious Diseases 2006, 6:35 http://www.biomedcentral.com/1471-2334/6/35
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involved. (4) The pooled mortality rate was 81.8% (5) In
the majority of the patients with fungal neutropenic ente-
rocolitis, no antimycotic therapy was described and possi-
bly not administered.
The frequencies of invasive fungal infections in neutro-
penic enterocolitis were lower than expected. In our own
patients from two studies, we observed fungal neutro-
penic enterocolitis in 11.8% (2/17) [4,23]. Autopsy stud-
ies reported frequencies up to more than 19% [10].
However, several selection and detection biases of these
methods of frequency calculation have to be considered.
On one hand, fungal neutropenic enterocolitis is proba-
bly underestimated, since histology, as the most specific
diagnostic method, is rarely obtained in living patients.
On the other hand, patients with more severe courses may
be selected because of the inclusion of surgical or patho-
logical studies that did not describe consecutive patients.
Furthermore, the diagnostic criteria in studies concerning
neutropenic enterocolitis are generally heterogeneous.
However, in most reported cases of invasive fungal infec-
tion, neutropenic enterocolitis was confirmed histopatho-
logically (Table 1).
Fungal infections other than Candida spp., particularly
Aspergillus fumigatus, are rare exceptions. Unfortunately,
only in a minority of reported cases, a species confirma-
tion is available. Among these patients, Candida albicans
occurred most frequently, but in some patients, flucona-
zole-resistant species such as Candida glabrata and Candida
krusei have been observed. In approximately half of the
patients, diagnosis of invasive fungal infection is estab-
lished by blood culture and in the other half by histology.
Bacteria are clearly the most important group of patho-
gens in neutropenic enterocolitis. Rates of bacteraemia
between 34% [27] and 82% [28] have been reported in
larger series. In most patients, development of neutro-
penic enterocolitis is probably a multifactorial process. In
our analysis, the term "causative pathogen" does not
mean "exclusively causative". We recognize that mostly
secondary infection of injured mucosa is responsible for
deterioration, complications and poorer outcome of the
patients. Furthermore, from a clinical and practical point
of view, the treatable factor infection and not hardly treat-
able factors such as toxic damage should be stressed.
The mortality of fungal neutropenic enterocolitis was very
high (81.8%). This pooled mortality rate may be biased
and slightly overestimated due to inclusion of 8 patients
from autopsy case series. Less severe cases may be moder-
ately underrepresented. However, it must be emphasised
that the course of fungal neutropenic enterocolitis is not
invariably fatal. Eight patients survived and the descrip-
tion of a 100% mortality rate reported by Starnes et al. and
cited by others [2,29] can not be confirmed. It was strik-
ing, that in the majority of cases with fungal neutropenic
enterocolitis, authors did not report or discuss the use of
antimycotics. One might speculate that this obviously low
grade of consideration of antifungal therapy in neutro-
penic enterocolitis might have contributed to the high
mortality rate.
Infections from Aspergillus spp. are very rare exceptions
(despite observation of two patients including one with
jejunal ulceration by Aspergillus in one of our studies [4]).
This rarity may be explained by the fact that Aspergillus
infections are typically acquired by inhalation and inva-
sive growth in the respiratory tract.
Evidence concerning empirical antifungal therapy of neu-
tropenic enterocolitis is still very limited. We found that
neither prospective nor high quality retrospective studies
concerning this issue in neutropenic enterocolitis are
available. In 33 patients with fungal neutropenic entero-
colitis, in reports of evidence levels 4 and 5, it was not
described that any antifungal therapy was given. In 20
patients with proven fungal neutropenic enterocolitis
more or less precise information regarding empirical or
microbiologically induced antifungal therapy was pro-
vided. Only in two of these patients empirical antimycotic
therapy (fluconazole) was clearly reported [21,22]. Many
other patients probably received antimycotics only after
detection of fungaemia. Unfortunately, patient numbers
and data quality are not sufficient to analyse, statistically,
the success of antimycotic therapies, especially empirical
use. Our analysis is limited by lack of additional individ-
ual information from the authors on antifungal therapy.
Possibly, many authors see no need for empirical antifun-
gal therapy. Only few authors of the relevant studies rec-
ommended empirical antifungal therapy [20,24,30].
Girmenia et al. suggested a semi-empirical selective ther-
apy with fluconazole based on the detection of Candida
mannoproteinaemia [24]. Micozzi et al. pointed out that
empirical administration of fluconazole in all febrile
patients could represent a way to prevent neutropenic
enterocolitis [20]. Wach recommended that conservative
therapy of neutropenic enterocolitis should include
antimycotic drugs but did not provide more specific rec-
ommendations [30]. D'Amato et al. stated that antifungal
treatment should be considered [31].
In the NCCN practice guidelines for fever and neutrope-
nia "consideration of antifungal coverage" is recom-
mended for febrile neutropenic patients with abdominal
pain or diarrhea [32]. In the IDSA guidelines for the use of
antimicrobial agents in neutropenic patients with cancer,
no specific recommendation concerning fungal neutro-
penic enterocolitis is provided [6]. However, one might
have the opinion that these patients fall within the scopeBMC Infectious Diseases 2006, 6:35 http://www.biomedcentral.com/1471-2334/6/35
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of the sections of these IDSA guidelines referring to the
treatment of neutropenic patients with unexplained fever.
They state that, although clinicians disagree as to when,
and even if, amphotericin B therapy should be introduced
empirically, most believe that the patient who remains
febrile and profoundly neutropenic for >5 days despite
the administration of broad-spectrum antibiotics in ade-
quate dosages, is a candidate for antifungal therapy [6].
So, should empirical antimycotic therapy in neutropenic
enterocolitis be recommended? If the answer is yes, when
should antimycotic therapy be started? Which drugs
should be used? We believe that application of the above
recommendations for FUO to our subgroup of patients is
justified on principle. All patients who remain febrile and
profoundly neutropenic for >5, days including those with
neutropenic enterocolitis should receive amphotericin B
empirically. Some patients, who are already febrile several
days before clinical signs of neutropenic enterocolitis
develop, will receive amphotericin B earlier as 6 days after
diagnosis of neutropenic enterocolitis.
The question whether the frequency and the microbio-
logical distribution of invasive fungal infections support
immediate empirical antimycotic therapy can not be
answered clearly from the literature data. If the moder-
ately low frequency of fungal pathogens is taken into con-
sideration, clinicians might not be willing to start
empirical antimycotic therapy with amphotericin B only
based on the diagnosis of neutropenic enterocolitis,
immediately on the first day of fever. Therefore, an earlier
start of empirical antimycotic therapy (like in patients
with pulmonary infiltrates) would not be preferred by
many.
However, some arguments could be made in favour of an
empirical use of fluconazole in neutropenic patients with
enterocolitis: (1) The drug has a low toxicity. (2) Candida
albicans is the leading fungal pathogen. (3) Patients with
neutropenic enterocolitis and a positive Candida manno-
protein test treated with fluconazole have been shown to
have a good prognosis [24]. (4) Fluconazole is an effective
drug in clinically stable, non-neutropenic patients with
candidaemia [33].
However, fluconazole is not a safe choice for treating non-
albicans candidaemia, especially when Candida krusei
(primary resistance) or Candida glabrata (dose-dependent
sensitivity) have been identified [34]. Many epidemiolog-
ical studies indicate that the proportion of non-albicans
Candida species is clearly increasing and around 50–60 %
[35-37]. Also, the empirical use of fluconazole must be
restricted to patients who did not receive azoles as anti-
fungal prophylaxis, since no improvement of antimycotic
coverage by fluconazole can be expected. Currently, a
major part of patients will be pretreated with itraconazole.
Our own meta-analysis suggests such an antimycotic
prophylaxis in long term neutropenic patients [38],
although this practice is still a matter of debate [39] and
although its impact on the incidence of neutropenic ente-
rocolitis is unclear. Furthermore – and this a very strong
argument against fluconazole for neutropenic enterocoli-
tis – many patients suffer from multiple infections or are
at least at high risk to develop a mould infection which
would not be covered by fluconazole. All substances that
have demonstrated efficacy in valid clinical trials of
empirical antifungal therapy for FUO are active against
Aspergillus spp. like liposomal amphotericin B [40], itraco-
nazole [41] and caspofungin [42].
Unfortunately, no data are available on the use of itraco-
nazole or other novel antimycotics, such as voriconazole
and caspofungin, in patients with proven fungal neutro-
penic enterocolitis nor on the empirical use of these
agents in this entity. A prospective multicenter study com-
paring empirical therapies, antibacterial agent vs. the
same antibacterial agent plus antimycotic, is warranted.
In our opinion, in patients with evidence of invasive fun-
gal neutropenic enterocolitis (in most cases by detection
of candidaemia) administration of amphotericin B,
caspofungin or voriconazole are appropriate choices.
However, in contrast to amphotericin B [4,22], we found
no paper reporting experiences with caspofungin or vori-
conazole in fungal neutropenic enterocolitis, but only
encouraging results from candidaemia trials [43,44]. Of
these latter drugs, caspofungin is indicated for patients
with renal dysfunction.
Conclusion
In patients with neutropenic enterocolitis, fungal patho-
gens play a relevant, but secondary role compared to bac-
teria. The frequency of invasive fungal neutropenic
enterocolitis is probably around 5% and its mortality
around 70–80%. The frequency may be underestimated,
since only few histological specimens are obtained in liv-
ing patients and the sensitivity of the diagnostic methods
is limited. Early empirical antimycotic therapy may be
therefore considered in neutropenic enterocolitis. How-
ever, evidence concerning therapy is very poor, since most
authors did not report or apply antifungal therapy. A clear
recommendation for empirical antimycotic therapy out-
side the context of prolonged fever can not be made.
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